Skip to main content
SpringerLink
Log in

Updates in Adjuvant Therapy

  • Chapter
Minimally Invasive Coloproctology

  • 790 Accesses

Abstract

Colorectal cancer is the third most common cancer worldwide. Surgery is the key treatment component in resectable colorectal cancer. However, recurrence after curative surgery is still a major problem and often causes major morbidity and mortality. In recent years, major advances have been achieved in molecular biology, surgery, radiotherapy, and drug treatment. These have contributed to improvements in early detection, prediction of prognosis, cure rate in early stage, and survival in advanced disease. Adjuvant chemotherapy is indicated for stage III colon cancer and selectively for high-risk stage II patients. Preoperative short-course radiotherapy or chemoradiotherapy for rectal cancer can improve local control, but the impact of preoperative adjuvant treatment for rectal cancer on overall survival is still uncertain. Oxaliplatin is beneficial as an adjuvant treatment in stage III colon cancer, though the benefit for patients older than 70 or as part of chemoradiotherapy for rectal cancer remains unproven.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jemal A, et al. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1893–907.

    Article  PubMed  Google Scholar 

  2. American Joint Committee on Cancer. AJCC cancer staging manual. 6th ed. New York: Springer-Verlag Publishers; 2002.

    Google Scholar 

  3. American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. New York: Springer-Verlag Publishers; 2010.

    Book  Google Scholar 

  4. Hari DM, et al. AJCC cancer staging manual 7th edition criteria for colon cancer: do the complex modifications improve prognostic assessment? J Am Coll Surg. 2013;217(2):181–90.

    Article  PubMed  Google Scholar 

  5. Laurie JA, et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol. 1989;7(10):1447–56.

    CAS  PubMed  Google Scholar 

  6. Moertel CG, et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes’ B2 colon cancer. J Clin Oncol. 1995;13(12):2936–43.

    CAS  PubMed  Google Scholar 

  7. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol. 1999;17(5):1356–63.

    Google Scholar 

  8. Mamounas E, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol. 1999;17(5):1349–55.

    CAS  PubMed  Google Scholar 

  9. Taal BG, Van Tinteren H, Zoetmulder FA. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer. 2001;85(10):1437–43.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. QUASAR Collaborative, G, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020–9.

    Article  Google Scholar 

  11. Sargent D, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27(6):872–7.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Labianca R, et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi64–72.

    CAS  PubMed  Google Scholar 

  13. Benson 3rd AB, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22(16):3408–19.

    Article  PubMed  Google Scholar 

  14. Ribic CM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349(3):247–57.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Sargent DJ, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219–26.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Sinicrope FA, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst. 2011;103(11):863–75.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Hutchins G, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol. 2011;29(10):1261–70.

    Article  PubMed  Google Scholar 

  18. Bertagnolli MM, et al. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer – a study of CALGB 9581 and 89803. J Clin Oncol. 2011;29(23):3153–62.

    Article  PubMed Central  PubMed  Google Scholar 

  19. O’Connell MJ, et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol. 2010;28(25):3937–44.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Venook AP, et al. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol. 2013;31(14):1775–81.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Gray RG, et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol. 2011;29(35):4611–9.

    Article  PubMed  Google Scholar 

  22. Kennedy RD, et al. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J Clin Oncol. 2011;29(35):4620–6.

    Article  PubMed  Google Scholar 

  23. Maak M, et al. Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. Ann Surg. 2013;257(6):1053–8.

    Article  PubMed  Google Scholar 

  24. Salazar R, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol. 2011;29(1):17–24.

    Article  PubMed  Google Scholar 

  25. Yothers G, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29(28):3768–74.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Tournigand C, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol. 2012;30(27):3353–60.

    Article  CAS  PubMed  Google Scholar 

  27. Zaanan A, et al. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol. 2010;21(4):772–80.

    Article  CAS  PubMed  Google Scholar 

  28. Gunderson LL, et al. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010;28(2):264–71.

    Article  PubMed Central  PubMed  Google Scholar 

  29. Wolmark N, et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst. 1988;80(1):30–6.

    Article  CAS  PubMed  Google Scholar 

  30. Moertel CG, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322(6):352–8.

    Article  CAS  PubMed  Google Scholar 

  31. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet. 1995;345(8955):939–44.

    Article  Google Scholar 

  32. O’Connell MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol. 1997;15(1):246–50.

    PubMed  Google Scholar 

  33. Moertel CG, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med. 1995;122(5):321–6.

    Article  CAS  PubMed  Google Scholar 

  34. Andre T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–51.

    Article  CAS  PubMed  Google Scholar 

  35. Andre T, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–16.

    Article  CAS  PubMed  Google Scholar 

  36. Kuebler JP, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25(16):2198–204.

    Article  CAS  PubMed  Google Scholar 

  37. Haller DG, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29(11):1465–71.

    Article  CAS  PubMed  Google Scholar 

  38. Saltz LB, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol. 2007;25(23):3456–61.

    Article  CAS  PubMed  Google Scholar 

  39. Van Cutsem E, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol. 2009;27(19):3117–25.

    Article  PubMed  Google Scholar 

  40. Allegra CJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011;29(1):11–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  41. de Gramont A, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 2012;13(12):1225–33.

    Article  PubMed  Google Scholar 

  42. Alberts SR, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012;307(13):1383–93.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  43. Taieb J, et al. Adjuvant FOLFOX4 with or without cetuximab (CTX) in patients (pts) with resected stage III colon cancer (CC): DFS and OS results and subgroup analyses of the PETACC-8 Intergroup Phase III Trial. Ann Oncol. 2012;23(suppl 9):abstr# LBA4.

    Google Scholar 

  44. Sargent DJ, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345(15):1091–7.

    Article  CAS  PubMed  Google Scholar 

  45. McCleary NJ, et al. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol. 2013;31(20):2600–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  46. van de Velde CJ, et al. EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. Eur J Cancer. 2014;50(1):1.e1–1.e34.

    Article  Google Scholar 

  47. Breugom AJ, et al. Quality assurance in the treatment of colorectal cancer: the EURECCA initiative. Ann Oncol. 2014;25(8):1485–92.

    Google Scholar 

  48. Gunderson LL, Sosin H. Areas of failure found at reoperation (second or symptomatic look) following “curative surgery” for adenocarcinoma of the rectum. Clinicopathologic correlation and implications for adjuvant therapy. Cancer. 1974;34(4):1278–92.

    Article  CAS  PubMed  Google Scholar 

  49. Kapiteijn E, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638–46.

    Article  CAS  PubMed  Google Scholar 

  50. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986;1(8496):1479–82.

    Article  CAS  PubMed  Google Scholar 

  51. Heald RJ. Total mesorectal excision is optimal surgery for rectal cancer: a Scandinavian consensus. Br J Surg. 1995;82(10):1297–9.

    Article  CAS  PubMed  Google Scholar 

  52. Glimelius B, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi81–8.

    CAS  PubMed  Google Scholar 

  53. Valentini V, et al. Multidisciplinary rectal cancer management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiother Oncol. 2009;92(2):148–63.

    Article  PubMed  Google Scholar 

  54. Heald RJ, et al. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978–1997. Arch Surg. 1998;133(8):894–9.

    Article  CAS  PubMed  Google Scholar 

  55. Law WL, Chu KW. Local recurrence following total mesorectal excision with double-stapling anastomosis for rectal cancers: analysis of risk factors. World J Surg. 2002;26(10):1272–6.

    Article  PubMed  Google Scholar 

  56. Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol. 2008;26(2):303–12.

    Article  PubMed  Google Scholar 

  57. Quirke P, West NP, Nagtegaal ID. EURECCA consensus conference highlights about colorectal cancer clinical management: the pathologists expert review. Virchows Arch. 2014;464(2):129–34.

    Article  CAS  PubMed  Google Scholar 

  58. MERCURY Study Group. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ. 2006;333(7572):779.

    Article  PubMed Central  Google Scholar 

  59. Colorectal Cancer Collaborative, G. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet. 2001;358(9290):1291–304.

    Article  Google Scholar 

  60. van Gijn W, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12(6):575–82.

    Article  PubMed  Google Scholar 

  61. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med. 1997;336(14):980–7.

    Article  Google Scholar 

  62. Folkesson J, et al. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23(24):5644–50.

    Article  PubMed  Google Scholar 

  63. Sauer R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–40.

    Article  CAS  PubMed  Google Scholar 

  64. Sauer R, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926–33.

    Article  CAS  PubMed  Google Scholar 

  65. Bujko K, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93(10):1215–23.

    Article  CAS  PubMed  Google Scholar 

  66. Ngan SY, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012;30(31):3827–33.

    Article  PubMed  Google Scholar 

  67. Bujko K, et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol. 2004;72(1):15–24.

    Article  CAS  PubMed  Google Scholar 

  68. Bujko K, et al. Does rectal cancer shrinkage induced by preoperative radio(chemo)therapy increase the likelihood of anterior resection? A systematic review of randomised trials. Radiother Oncol. 2006;80(1):4–12.

    Article  PubMed  Google Scholar 

  69. Francois Y, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol. 1999;17(8):2396.

    CAS  PubMed  Google Scholar 

  70. Glehen O, et al. Long-term results of the Lyons R90-01 randomized trial of preoperative radiotherapy with delayed surgery and its effect on sphincter-saving surgery in rectal cancer. Br J Surg. 2003;90(8):996–8.

    Article  CAS  PubMed  Google Scholar 

  71. Pettersson D, et al. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg. 2010;97(4):580–7.

    Article  CAS  PubMed  Google Scholar 

  72. Pettersson D, et al. Impaired postoperative leucocyte counts after preoperative radiotherapy for rectal cancer in the Stockholm III Trial. Br J Surg. 2013;100(7):969–75.

    Article  CAS  PubMed  Google Scholar 

  73. Boulis-Wassif S, et al. Final results of a randomized trial on the treatment of rectal cancer with preoperative radiotherapy alone or in combination with 5- fluorouracil, followed by radical surgery. Trial of the European Organization on Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. Cancer. 1984;53(9):1811–8.

    Article  CAS  PubMed  Google Scholar 

  74. Bosset JF, et al. Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance. Report of the 22921 randomised trial conducted by the EORTC Radiotherapy Group. Eur J Cancer. 2004;40(2):219–24.

    Article  CAS  PubMed  Google Scholar 

  75. Bosset JF, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114–23.

    Article  CAS  PubMed  Google Scholar 

  76. Gerard JP, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24(28):4620–5.

    Article  PubMed  Google Scholar 

  77. Braendengen M, et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol. 2008;26(22):3687–94.

    Article  CAS  PubMed  Google Scholar 

  78. Ngan SY, et al. Acute adverse events in a randomized trial of short-course versus long-course preoperative radiotherapy for T3 adenocarcinoma of rectum: a Trans-Tasman Radiation Oncology Group trial (TROG 01.04). Eur J Cancer Suppl. 2007;5(4):237.

    Article  Google Scholar 

  79. Aschele C, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29(20):2773–80.

    Article  CAS  PubMed  Google Scholar 

  80. Gerard JP, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol. 2010;28(10):1638–44.

    Article  CAS  PubMed  Google Scholar 

  81. Gerard JP, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol. 2012;30(36):4558–65.

    Article  CAS  PubMed  Google Scholar 

  82. Rodel C, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012;13(7):679–87.

    Article  PubMed  Google Scholar 

  83. Allegra C, et al. Neoadjuvant therapy for rectal cancer: mature results from NSABP protocol R-04. J Clin Oncol. 2014;32(suppl 3):abstr 390.

    Google Scholar 

  84. Petersen SH, et al. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev. 2012;(3):CD004078.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Care Centre, Private Practice, Room 1303, 26 Nathan Road, Kowloon, Hong Kong, SAR China

    Wai Man Sze

Authors
  1. Wai Man Sze
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wai Man Sze .

Editor information

Editors and Affiliations

  1. Department of Surgery, Matilda International Hospital, HongKong, China

    William C S Meng

  2. Department of Surgery, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China

    Hester Y S Cheung

  3. City Medical Center Room 833, 8/F, Office Tower 1, Grand Plaza, Hong Kong, China

    David T Y Lam

  4. Department of Surgery, Prince of Wales Hospital The Chinese University of Hong Kong, Hong Kong, China

    Simon S M Ng

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Sze, W.M. (2015). Updates in Adjuvant Therapy. In: Meng, W., Cheung, H., Lam, D., Ng, S. (eds) Minimally Invasive Coloproctology. Springer, Cham. https://doi.org/10.1007/978-3-319-19698-5_23

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-19698-5_23

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-19697-8

  • Online ISBN: 978-3-319-19698-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation